Tardive dyskinesia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 05 Jun 2026 10:53:46 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Tardive dyskinesia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of (+)-α-Dihydrotetrabenazine for Treating Tardive Dyskinesia in Patients with Schizophrenia, Mood, or Gastrointestinal Disorders https://clinicaltrials.eu/trial/study-on-the-effects-of-%ce%b1-dihydrotetrabenazine-for-treating-tardive-dyskinesia-in-patients-with-schizophrenia-mood-or-gastrointestinal-disorders/ Wed, 29 Apr 2026 15:03:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-%ce%b1-dihydrotetrabenazine-for-treating-tardive-dyskinesia-in-patients-with-schizophrenia-mood-or-gastrointestinal-disorders/ This clinical trial is focused on studying a condition known as tardive dyskinesia, which is a movement disorder that can occur in people who have been taking certain medications for mental health conditions. The trial will test a treatment called (+)-α-dihydrotetrabenazine, also known as (+)-α-DHTBZ, which is given as an oral solution. The purpose of the study is to evaluate how effective, safe, and tolerable this treatment is for people with tardive dyskinesia.

Participants in the study will receive different doses of the treatment to find the most effective and safe amount. The study will last for a period of eight weeks, during which participants will take the medication either once or twice a day. Throughout the study, participants will be monitored for any changes in their symptoms and any side effects they might experience. This will help researchers understand how well the treatment works and how it affects the body.

The study will also involve regular check-ups, including physical exams and tests to monitor participants’ health. These tests will include assessments of movement symptoms, as well as checks on overall health, such as heart function and mental well-being. The information gathered from this study will contribute to understanding how (+)-α-DHTBZ can be used to help people with tardive dyskinesia manage their symptoms more effectively.

]]> Study on the Effects of (+)-α-Dihydrotetrabenazine for Patients with Moderate to Severe Tardive Dyskinesia https://clinicaltrials.eu/trial/study-on-the-effects-of-%ce%b1-dihydrotetrabenazine-for-patients-with-moderate-to-severe-tardive-dyskinesia/ Wed, 29 Apr 2026 14:59:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-%ce%b1-dihydrotetrabenazine-for-patients-with-moderate-to-severe-tardive-dyskinesia/ This clinical trial is focused on studying a condition known as tardive dyskinesia, which involves involuntary movements that can be bothersome and affect daily life. The trial will test a treatment called (+)-α-dihydrotetrabenazine, also known by its code name ADE513. This medication is provided as an oral solution, meaning it is taken by mouth in liquid form. The purpose of the study is to evaluate how effective ADE513 is in reducing the abnormal movements associated with tardive dyskinesia.

The study is divided into two parts. In the first part, all participants will receive the medication openly, meaning everyone knows they are taking ADE513. In the second part, participants will be randomly assigned to receive either ADE513 or a placebo, without knowing which one they are taking. This is done to compare the effects of the medication against no active treatment. The study will last for a period of up to 18 weeks, during which participants will attend regular visits to monitor their progress and any changes in their symptoms.

Throughout the study, participants will be assessed on their involuntary movements using a scale called the AIMS (Abnormal Involuntary Movement Scale). This will help determine any improvements in their condition. The trial aims to find out if ADE513 can provide significant relief from the symptoms of tardive dyskinesia, potentially offering a new treatment option for those affected by this condition.

]]> Safety Study of (+)-α-Dihydrotetrabenazine for Patients with Moderate to Severe Tardive Dyskinesia https://clinicaltrials.eu/trial/safety-study-of-%ce%b1-dihydrotetrabenazine-for-patients-with-moderate-to-severe-tardive-dyskinesia/ Wed, 29 Apr 2026 14:30:32 +0000 https://clinicaltrials.eu/trial/safety-study-of-%ce%b1-dihydrotetrabenazine-for-patients-with-moderate-to-severe-tardive-dyskinesia/ This clinical trial is focused on studying the safety of a treatment for tardive dyskinesia, a condition characterized by involuntary movements, often affecting the face and body. The treatment being tested is called (+)-α-dihydrotetrabenazine, also known by its code name ADE513. This medication is provided as an oral solution, which means it is taken by mouth in liquid form.

The purpose of the study is to evaluate how safe and tolerable this treatment is when used over a long period. Participants in the study will receive the medication and be monitored for any changes in their condition and any side effects they might experience. The study will last for up to 54 weeks, during which time participants will have regular check-ups to assess their health and the effects of the treatment.

Throughout the study, participants will be asked to complete certain assessments to help researchers understand the impact of the treatment on their symptoms. The study aims to provide valuable information on the long-term use of (+)-α-dihydrotetrabenazine for managing tardive dyskinesia, contributing to better treatment options for those affected by this condition.

]]>